Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Seo Y, Aparici CM, Cooperberg MR, Konety BR, Hawkins RA.

J Nucl Med. 2010 Jan;51(1):31-6. doi: 10.2967/jnumed.109.067108. Epub 2009 Dec 15.

2.

Capromab Pendetide imaging of prostate cancer.

Haseman MK, Rosenthal SA, Polascik TJ.

Cancer Biother Radiopharm. 2000 Apr;15(2):131-40. Review.

PMID:
10803318
3.

Update on fused capromab pendetide imaging of prostate cancer.

Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G.

Clin Prostate Cancer. 2005 Mar;3(4):230-8. Review.

PMID:
15882479
4.

Indium-111 capromab pendetide in the management of recurrent prostate cancer.

Manyak MJ.

Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81. doi: 10.1586/14737140.8.2.175. Review.

PMID:
18279057
5.

Capromab pendetide. A review of its use as an imaging agent in prostate cancer.

Lamb HM, Faulds D.

Drugs Aging. 1998 Apr;12(4):293-304. Review.

PMID:
9571393
6.

Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.

Rosenthal SA, Haseman MK, Polascik TJ.

Tech Urol. 2001 Mar;7(1):27-37. Review.

PMID:
11272670
7.

Functional imaging for prostate cancer: therapeutic implications.

Mari Aparici C, Seo Y.

Semin Nucl Med. 2012 Sep;42(5):328-42. doi: 10.1053/j.semnuclmed.2012.04.004. Review.

Supplemental Content

Support Center